Abstract
The results of the largest, double-blind, placebo-controlled, multicentre, multinational randomized clinical trial (RCT) evaluating the effects of human growth hormone (hGH) on clinical outcome in 695 haemodialysed adults are published in this issue [1]. Designed to answer the important question whether hGH therapy might improve the notoriously poor survival in patients on dialysis, the OPPORTUNITY trial will enter the collective memory of the nephrology community as a paradigmatic case illustrating the unfortunate dependence of clinical pharmacological research on the short-term interest of industry sponsors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
